Purpose of Review <p><i>Staphylococcus aureus</i> is a major public health concern due to its ability to cause severe and complicated infections across multiple organs. Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) poses a significant global threat, as it readily acquires resistance to various antibiotic classes. Its strong biofilm-forming capacity further complicates treatment in clinical settings. This review aims to explore the therapeutic potential of bacteriophages (phages) against <i>S. aureus</i> infections, highlighting their advantages, limitations, and challenges.</p> Recent Findings <p>Phage therapy has re-emerged as a promising approach for combating bacterial pathogens, including <i>S. aureus</i>. Lytic bacteriophages have demonstrated potential in managing localized and systemic bacterial infections. Recent studies have provided insights into the efficacy of phage therapy, suggesting it could complement or replace traditional antibiotic treatments, especially for multidrug-resistant strains like MRSA.</p> Summary <p>The increasing prevalence of antibiotic resistance in S. aureus necessitates innovative treatment strategies. Phage therapy offers a viable alternative with significant therapeutic promise. However, further research must focus on addressing challenges such as resistance development, regulatory hurdles, and optimization of therapeutic protocols.</p> Graphical Abstract <p></p>